AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
about
Drug Discovery Targeting Bromodomain-Containing Protein 4.Selective BET bromodomain inhibition as an antifungal therapeutic strategyTranslational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.Generation of stable PDX derived cell lines using conditional reprogramming.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1.BRD4 facilitates replication stress-induced DNA damage response.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
P2860
Q30352390-26339646-3768-4B5A-A048-1D3449DD4393Q30354737-C133393F-5942-4F14-A961-804401666509Q33440695-A29162DE-6F4E-45C1-A796-069EE5A0CC9CQ38668641-55F7C78F-983F-4776-9CE6-B7F6F9F48A1AQ38679327-304346FC-9E78-44EB-A676-C93915410755Q38707684-84C61B3D-6878-46BE-A598-155B1569237EQ39207675-9D04CBAD-2FFA-49CC-B061-BB321DBEA057Q47356048-7835C66E-2029-460D-9D69-A3B03C714D56Q49843607-A03C76F5-D0AB-4FED-981B-4D3011885270Q52349061-74B71195-B8B7-471C-823E-ABBAF27BE4AEQ52595313-556226BB-715E-4DB7-A579-1F170BBB0860Q54982413-597BFC4B-47D7-410C-A6E8-BB1C845E6D9BQ55281964-BBAB238B-F347-451C-9A63-46E0FA5A9623Q55664994-733D09CC-937E-4672-8B6A-E2CADF62F66CQ57299887-69454ED0-3E0B-41AD-9685-15867F33C2CF
P2860
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
AZD5153: A Novel Bivalent BET ...... inst Hematologic Malignancies.
@en
type
label
AZD5153: A Novel Bivalent BET ...... inst Hematologic Malignancies.
@en
prefLabel
AZD5153: A Novel Bivalent BET ...... inst Hematologic Malignancies.
@en
P2093
P1476
AZD5153: A Novel Bivalent BET ...... inst Hematologic Malignancies.
@en
P2093
Alfred A Rabow
Austin Dulak
Corinne Reimer
Deborah Lawson
Edwin Clark
Garrett W Rhyasen
Gordon B Mills
Graeme Walker
Greg O'Connor
Huawei Chen
P304
P356
10.1158/1535-7163.MCT-16-0141
P577
2016-08-29T00:00:00Z